Effect of a special cream on dry skin and itching in cancer patients receiving anti-EGFR treatment
Official title: Studio Sulla Efficacia Di Una Crema Emolliente Contenente Pre E Postbiotici E Niacinamide 4% Nel Trattamento Della Xerosi Cutanea E Del Prurito in Pazienti Oncologici in Trattamento Con Anti-EGFR
Run by Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse · NCT06868771 · Data updated 2026-11-12
This study is testing a special cream to see if it can help cancer patients on anti-EGFR treatment with dry skin and itching.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 164 (estimated) |
| Sponsor | Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse Academic / other |
| Locations | 1 site (Roma, ROMA) |
| Status | Recruiting |
| Started | July 29, 2022 |
| Main results expected | April 30, 2023 |
| Study ends | April 30, 2025 |
| Registry record updated | March 11, 2025 |
| Trial ID | NCT06868771 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who have been receiving anti-EGFR therapy for more than three months.
✕Probably not a fit
Patients with severe skin reactions or those with a history of certain skin conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of a topical emollient cream containing pre and postbiotics along with 4% niacinamide in treating skin xerosis and itching in patients undergoing anti-EGFR therapy for cancer. The research focuses on addressing common dermatological side effects associated with EGFR inhibitors, which can significantly impact the quality of life of patients. Participants will be treated with either the study cream or a 10% urea-based preparation to compare their effects on skin hydration and itching relief. The study aims to provide a better management strategy for skin-related adverse events in oncological patients.
Why it matters
Potential benefit: If successful, this treatment could significantly improve skin hydration and reduce itching, enhancing the quality of life for cancer patients undergoing anti-EGFR therapy.
How similar studies have gone: While there are few studies directly comparing similar treatments, existing literature suggests that emollients can be beneficial for skin hydration in xerosis, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. patients aged 18 who have been receiving anti-EGFR therapy for more than three months, 2. signature of the informed consent. Exclusion Criteria: 1. Patients diagnosed with Grade II papulopustulous skin reaction according to the Common Terminology Criteria for Adverse Event (CTCAE) scale at the time of enrolment; 2. concomitant use of emollients and/or steroidal creams; 3. personal history of xerotic pathologies (e.g. lichen, ichthyosis) and/or itching of n.d.d.; 4. inability to provide informed consent or inability to complete the procedures required for enrollment in the study.
Where it's running
-
Irccs Fondazione Policlinico Gemelli
Roma, Roma, Italy Recruiting
Study contacts
- Principal investigator: Ketty MD Peris — Irccs Fondazione Policlinico Gemelli
- Study coordinator: Ketty MD Peris
- Email: ketty.peris@unicatt.it
- Phone: 0630154211
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment of skin issues caused by cancer medications
This study is testing a new gel to see if it can help people with skin problems caused by cancer medications feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.